ScoreWhy is Oncolys BioPharma, Inc. ?
1
Poor Management Efficiency with a low ROE of 0%
- The company has reported losses. Due to this company has reported negative ROE
2
Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of -349.00
- Poor long term growth as Operating profit has grown by an annual rate 1.24% of over the last 5 years
- Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of -349.00
- The company has reported losses. Due to this company has reported negative ROE
3
Poor long term growth as Operating profit has grown by an annual rate 1.24% of over the last 5 years
4
Risky -
- The stock is trading risky as compared to its average historical valuations
- Over the past year, while the stock has generated a return of 364.60%, its profits have risen by 21.6%
Real-Time Research ReportHow much should you sell?
- All quantity irrespective of whether you are making profits or losses
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to re-enter? - We will constantly monitor the company and review our call based on new data
Is Oncolys BioPharma, Inc. for you?
High Risk, High Return
Absolute
Risk Adjusted
Volatility
Oncolys BioPharma, Inc.
373.26%
2.80
108.72%
Japan Nikkei 225
60.14%
2.04
29.37%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
-36.50%
EBIT Growth (5y)
1.24%
EBIT to Interest (avg)
-352.14
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.76
Sales to Capital Employed (avg)
0.01
Tax Ratio
0.26%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
0
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
20.75
EV to EBIT
-43.23
EV to EBITDA
-43.23
EV to Capital Employed
92.71
EV to Sales
2267.57
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-214.48%
ROE (Latest)
-46.15%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
Mildly Bullish
No Trend
OBV
No Trend
No Trend
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend16What is working for the Company
NET SALES(HY)
Higher at JPY 503.09 MM
NET PROFIT(HY)
Higher at JPY -762.15 MM
RAW MATERIAL COST(Y)
Fallen by -0.14% (YoY
DEBTORS TURNOVER RATIO(HY)
Highest at 0.76 times
-12What is not working for the Company
INTEREST(Q)
Highest at JPY 5.85 MM
Here's what is working for Oncolys BioPharma, Inc.
Net Sales
At JPY 503.09 MM has Grown at 1,662.38%
Year on Year (YoY)MOJO Watch
Sales trend is very positive
Net Sales (JPY MM)
Net Sales
Higher at JPY 503.09 MM
than preceding 12 month period ended Jun 2026MOJO Watch
In the half year the company has already crossed sales of the previous twelve months
Net Sales (JPY MM)
Net Profit
Higher at JPY -762.15 MM
than preceding 12 month period ended Jun 2026MOJO Watch
In the half year the company has already crossed Net Profit of the previous twelve months
Net Profit (JPY MM)
Debtors Turnover Ratio
Highest at 0.76 times
in the last five Semi-Annual periodsMOJO Watch
Company has been able to sell its Debtors faster
Debtors Turnover Ratio
Raw Material Cost
Fallen by -0.14% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
Here's what is not working for Oncolys BioPharma, Inc.
Interest
At JPY 5.85 MM has Grown at 95.95%
period on period (QoQ)MOJO Watch
Rising interest cost signifies increased borrowings
Interest Paid (JPY MM)
Interest
Highest at JPY 5.85 MM
in the last five periods and Increased by 95.95% (QoQ)MOJO Watch
Rising interest cost signifies increased borrowings
Interest Paid (JPY MM)
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
